UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
-
Recruiting
- Pediatrics
- On Hold
Conditions
Diffuse Midline Glioma
This study will enroll children and young adults (between the ages of 3 to 21 years old) with newly diagnosed Diffuse Midline Gliomas (DMGs, HLA-A*0201 positive and H3.3K27M positive).
Conditions
Glioma
This project will use cutting-edge epigenomic science to develop and validate a new generation of immune biomarkers to improve glioma survival prognostication and will provide clinically applicable tools to identify tumor IDH status prior to surgical intervention and evaluate the effects of radiation and immunotherapy.
Conditions
Medulloblastoma
The study will use a new treatment approach based on the molecular characteristics of each participant’s tumor by testing the feasibility of performing real-time drug screening on tissue taken during surgery, and of having a specialized tumor board assign a treatment plan based on the results of this screening and genomic sequencing.
Conditions
Meningioma
This study aims to better understand the challenges and symptoms that meningioma survivors are living with to improve treatment strategies and follow-up care for with patients with meningioma.
Conditions
Ependymoma
This is a single arm, 2 strata multi-center study that will be conducted through the Pacific Pediatric Neuro-oncology Consortium (PNOC).
Stratum A: children (ages 3-17) with recurrent or progressive malignant brain tumors
Conditions
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Brainstem Glioma
Diffuse Midline Glioma
Medulloblastoma
Choroid Plexus Tumors
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
The purpose is to evaluate cognitive, social, emotional, and behavioral functioning over time in patients already enrolled in a Children’s Oncology Group Phase III clinical trial.
Conditions
Craniopharyngioma
This phase II trial will assess the tolerability and efficacy of combination therapy with PD-1 (nivolumab) and pan-RAF-kinase (DAY101) inhibition for the treatment of children and young adults with craniopharyngioma.
Conditions
Diffuse Midline Glioma
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Pleomorphic xanthoastrocytoma (grades II-III)
Glioblastoma (grade IV)
Brainstem Glioma
Ependymoma
This phase I clinical trial will evaluate ONC206 alone or in combination with radiation therapy in treating pediatric patients with newly diagnosed or recurrent DMGs, or other recurrent primary malignant brain tumors.
Conditions
Glioma
Astrocytoma
Oligodendroglioma
Ependymoma
The goal of this phase I clinical trial is to demonstrate that a metabolic imaging technology can safely be used in patients with gliomas to help study treatment effects.
Conditions
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Glioma
Glioblastoma (grade IV)
Anaplastic astrocytoma (grade III)
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Natural killer (NK) cells are immune cells that recognize and get rid of abnormal cells in the body, including tumor cells and cells infected by viruses. NK cells have been shown to kill different types of cancer, including brain tumors in laboratory settings.
Conditions
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
The goal of this registry study is to collect more information to help identify clinical, biological, and imaging factors that can predict outcomes for ATRT.
Conditions
Meningioma
This phase II clinical trial will evaluate the safety and efficacy of stereotactic radiosurgery and pembrolizumab in treating patients with recurrent meningioma (grades I-III).